Browsing by Author "Makatsoris, T."
Now showing items 1-9 of 9
-
Article
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
Pentheroudakis, George; Kotoula, V.; Roock, W. De; Kouvatseas, G.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Xanthakis, I.; Sgouros, J.; Televantou, D.; Kafiri, G.; Tsamandas, A. C.; Razi, E. D.; Galani, E.; Bafaloukos, Dimitrios; Efstratiou, I.; Bompolaki, I.; Pectasides, Dimitrios; Pavlidis, Nicholas; Tejpar, S.; Fountzilas, George (2013)Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order ...
-
Article
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression
Razi, E. D.; Kalogeras, K. T.; Kotoula, V.; Eleftheraki, A. G.; Nikitas, N.; Kronenwett, R.; Timotheadou, E.; Christodoulou, C.; Pectasides, Dimitrios; Gogas, H.; Wirtz, R. M.; Makatsoris, T.; Bafaloukos, Dimitrios; Aravantinos, Gerasimos; Televantou, D.; Pavlidis, Nicholas; Fountzilas, George (2012)Background: Chemokines are important in cell migration and are thought to play a key role in metastasis. We explored the prognostic significance of C-X-C ligand-motif (CXCL) 12, CXCL13, and receptor (CXCR) 5 on disease-free ...
-
Article
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, Anna; Maniadakis, N.; Aravantinos, Gerasimos; Syrigos, K.; Bamias, A. T.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H. P.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Pavlidis, Nicholas; Daniilidis, J. (2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...
-
Article
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: A hellenic cooperative oncology group phase II study
Fountzilas, George; Ch, F. Tolis; Kalogera-Fountzila, Anna; Misailidou, D.; Tsekeris, P.; Karina, M.; Nikolaou, A.; Samantas, E.; Makatsoris, T.; Athanassiou, E.; Skarlos, Dimosthenis V.; Bamias, A. T.; Zamboglou, N.; Economopoulos, T.; Karanastassi, S.; Pavlidis, Nicholas; Daniilidis, J. (2005)The primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until ...
-
Article
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
Briassoulis, E. Ch; Samantas, E.; Kalofonos, H. P.; Skarlos, Dimosthenis V.; Makatsoris, T.; Christodoulou, C.; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2005)The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. ...
-
Article
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: A study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
Pliarchopoulou, K.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Eleftheraki, A. G.; Batistatou, Anna; Bobos, M.; Soupos, N.; Polychronidou, G.; Gogas, H.; Samantas, E.; Christodoulou, C.; Makatsoris, T.; Pavlidis, Nicholas; Pectasides, Dimitrios; Fountzilas, George (2013)Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 ...
-
Article
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study
Psyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, Anna; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, Gerasimos; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, Dimitrios; Pavlidis, Nicholas; Economopoulos, T.; Fountzilas, George (2012)Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the ...
-
Article
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: A translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
Pentheroudakis, George; Kotoula, V.; Fountzilas, E.; Kouvatseas, G.; Basdanis, G.; Xanthakis, I.; Makatsoris, T.; Charalambous, E.; Papamichael, D.; Samantas, E.; Papakostas, P.; Bafaloukos, Dimitrios; Razi, E. D.; Christodoulou, C.; Varthalitis, I.; Pavlidis, Nicholas; Fountzilas, George (2014)Background: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor ...